US FDA approves updated COVID vaccines for 2026-27 season
The updated shots target the XFG variant and are approved for older adults and younger people with certain high-risk conditions, Moderna said.
- On Thursday, the U.S. Food and Drug Administration approved Moderna's updated Spikevax and mNEXSPIKE vaccines for the 2026-27 season, targeting the JN.1-lineage XFG subvariant of SARS-CoV-2.
- Following an expert panel's May recommendation to prioritize the XFG variant, regulators also authorized updated COVID-19 vaccines from Pfizer-BioNTech and Novavax-Sanofi on the same day.
- Moderna Chief Executive Officer Stéphane Bancel noted that COVID-19 caused up to 2.3 million outpatient visits last year. Updated Spikevax is approved for ages 6 months through 64 years with underlying conditions and all adults 65 and older.
- Myocarditis and pericarditis have occurred most commonly in males 12 years through 24 years of age following mRNA vaccination. Recipients should seek immediate medical attention for chest pain or shortness of breath within 2 weeks of vaccination.
- Beyond the United States, the Spikevax formula has already received regulatory approval in Europe, the United Kingdom, Switzerland, Singapore, and South Korea, with additional applications under review globally.
54 Articles
54 Articles
FDA Approves New COVID-19 Jabs For Specific Populations – 100PercentFedUp.com – by Danielle
The Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 jabs, the company announced. “Today we announced that the […] The post FDA Approves New COVID-19 Jabs For Specific Populations appeared first on 100PercentFedUp.com.
FDA Approves New Covid Vaccines
The FDA approved new COVID-19 vaccines to be used this fall. In a press statement on the matter, Moderna said their Spikevax vaccine is to be used in those aged six months to 64 years old “with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.” Another vaccine for COVID-19, called mNEXSPIKE, is “approved for individuals 12 through 64 years of age with at least…
It is anticipated that these vaccines will be available in the coming days, amid a significant increase in infections in several regions of the US.
Coverage Details
Bias Distribution
- 66% of the sources are Center
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
